GE HealthCare to buy Sofie Biosciences for $945 million
GE HealthCare (GEHC) announced its intention to acquire Sofie Biosciences for $945 million in cash. The deal aims to bolster GE HealthCare's radiopharmaceutical business, enhancing its capabilities in manufacturing and distributing PET imaging drugs.
Medical device maker GE HealthCare said on Monday it will buy privately held Sofie Biosciences for $945 million in cash, in a move that expands its ability to manufacture and distribute PET imaging drugs. The acquisition will also give GE HealthCare US rights to FAPI-74, an experimental product.